Literature DB >> 6604101

The immunologic response of congenitally athymic rats to Schistosoma mansoni infection. I. In vivo studies of resistance.

S M Phillips, A G Bentley, G Linette, B L Doughty, M Capron.   

Abstract

The responses of congenitally athymic (Nu/Nu) rats to an initial exposure and to re-exposure to Schistosoma mansoni were compared to those manifested by thymic reconstituted (Nu/Nu*TxR), heterozygous littermate controls (Nu/+) and the highly characterized Fischer rat strain. Congenitally athymic rats rejected the developing worms of an initial infection more slowly than did thymic reconstituted or heterozygous animals. These latter responses were highly comparable to those demonstrated by the Fischer rat. In addition, the congenitally athymic rats manifested lower peripheral blood eosinophilia in response to infection. Resistance to reinfection in athymic animals was impaired and associated with a decreased immunoinflammatory histologic response to hepatic intravascular parasites and to eggs lodged in the hepatic vasculature. There was little evidence of inflammatory responses involving degranulating eosinophils, lymphocytes, or macrophages in the athymic rats. Finally, athymic animals produced antibody that was less capable of passively transferring resistance in adoptive-challenge experiments; however, antibody produced in heterozygous animals conferred significant resistance when adoptively transferred to athymic animals. These results suggest that resistance to initial and subsequent challenge by S. mansoni infections in the rat is highly reliant upon T-dependent mechanisms that result in the production of antibody-dependent, possibly cell-mediated resistance. Additional studies utilizing in vitro analysis of a variety of antibody functions to define the mechanisms of T-dependent immunologic resistance in the congenitally athymic rat are the subject of the accompanying manuscript.

Entities:  

Mesh:

Year:  1983        PMID: 6604101

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Human immune responses to Schistosoma mansoni vaccine candidate antigens.

Authors:  A Ribeiro de Jesus; I Araújo; O Bacellar; A Magalhães; E Pearce; D Harn; M Strand; E M Carvalho
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  T-cell-dependent immunity and thrombocytopenia in rats infected with Plasmodium chabaudi.

Authors:  H Watier; C Verwaerde; I Landau; E Werner; J Fontaine; A Capron; C Auriault
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

3.  The T-cell mediated immune response to Schistosoma mansoni. I. Generation of stage-specific, MHC-restricted proliferative T-cell clones to soluble egg antigens.

Authors:  N K Mak; C J Sanderson
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

4.  Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats.

Authors:  T G Moreels; R J Nieuwendijk; J G De Man; B Y De Winter; A G Herman; E A Van Marck; P A Pelckmans
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

5.  Total and specific IgE in serum and cerebrospinal fluid of rats and guinea pigs infected with Angiostrongylus cantonensis.

Authors:  O Pérez; M Lastre; M Capron; J L Neyrinck; T Jouault; H Bazin; A Capron
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

6.  Generation and functional analysis of T cell lines and clones specific for schistosomula released products (SRP-A).

Authors:  M Damonneville; F Velge; C Verwaerde; J Pestel; C Auriault; A Capron
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

7.  Profiles of Th1 and Th2 cytokines after primary and secondary infection by Schistosoma mansoni in the semipermissive rat host.

Authors:  C Cêtre; C Pierrot; C Cocude; S Lafitte; A Capron; M Capron; J Khalife
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.